Published in final edited form as:

Tetrahedron Lett. 2013 October 9; 54(41): 5555–5567. doi:10.1016/j.tetlet.2013.05.153.

Asymmetric Synthesis of the C1-C6 Portion of the Psymberin Using an Evans Chiral Auxiliary

Ashutosh Pal, Zhenghong Peng, Paul T. Schuber Jr., Basvoju A. Bhanu Prasad, and William G. Bornmann*

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030

Abstract

The C1-C6 region of the potent cytotoxic agent psymberin has been synthesized. The key transformations of the synthesis are an auxiliary-controlled addition of a Sn(II)-glycolate enolate to an aldehyde to yield the *anti* aldol product and transforming the primary alcohol into a terminal olefin utilizing organoselenium chemistry.

1. Introduction

In 2004, two groups independently reported the isolation and structural elucidation of a constitutionally identical acyl aminal **1** (Fig. 1). Pettit¹ isolated the extremely potent toxin from the South Pacific sponge *Ircinia ramose* whereas Crews² and coworkers also obtained the acyl aminal **1** from the crude extracts of an inconspicuous sponge, *psammocinia* sp., located from the waters of Papua New Guinea. The Pettit group named the compound as irciniastatin A and the Crews group named it as psymberin on the basis of its proposed biogenesis from symbiotic bacteria.³

Psymberin most closely resembles the pederin family⁴ of natural products defined by the presence of a functionalized cyclic ether derivative, but psymberin is unique to the pederin family (Fig. 1) because of the presence of a highly substituted dihydroisocoumarin moiety as well as a terminal six carbon amide appendage. The configuration of the amide side chain of psymberin and irciniastatin, was previously reported. Initially the stereochemical assignment at the C4 position and the 5*S* configuration was proposed based on the analogy to other natural products in the pederin family. Recently, William's and coworkers⁵ reported the stereochemical assignment of the C1-C6 region using ¹H and ¹³C NMR chemical shift homology and a corroborating X-ray crystal structure. They postulated that the stereocenters at C4 and C5 have an anti-relationship. Floreancig and coworkers⁶ established the stereochemical configuration of this fragment to be the 4*S*, 5*S* by the syntheses of all four stereoisomers of psymberic acid and comparison of the acid mediated cyclization products of these isomers to the product of psymberin's acidic methanolysis. Later De Brabander and coworkers⁷ and Xianhai and coworkers⁸ synthesized and made a complete stereochemical

*Corresponding author. Tel.: +1-713-563-0081; fax: +1-713-563-1878; wbornmann@mdanderson.org.

Supplementary Material

¹H and ¹³C NMR spectra of all new compounds can be found for free of charge via the internet at <http://dx.doi.org/>

assignment of psymberin with an *S*-configuration at C4 and they concluded that psymberin and irciniastatin A were structurally identical. Other synthetic approaches to psymberin were attempted by Smith⁹, Crimmins¹⁰ as well as an interesting approach to the amide side chain by Iwabachi.¹¹ Recently Smith¹² and De Brabander¹³ have also developed a second generation synthesis of this family of natural products.

Psymberin also displays some unique biological activity which was discovered at the SCI Development Therapeutic in vitro Screening Program. Psymberin displayed exceptional cytotoxicity below 2.5 nM against one colon cell cancer line (HCT-116) three melanoma (MALME-3M, SK-MEL-5, and UACCC-62) and a breast (MDA-MB-435) cancer cell line.^{2,14} Recently De Brabander has revealed some fascinating structure-activity relationships (SAR) as well as biochemical studies suggesting that psymberin may have more than one biological function.¹⁵ These interesting structural features as well as the interesting biological activity render this compound a synthetic target.

2 Results and discussions

Here we report the synthesis of anti-isomer of methyl ester of psymberic acid (C1-C6 fragment) using the auxiliary-controlled aldol addition of Sn(II)-glycolate enolate of **8** to aldehyde **7**, which provided adduct **6** with moderate diastereoselection (>88% ee) and showed all spectral data were identical with the anti-isomer of (2*S*, 3*S*)-2-hydroxy-3-methoxy-5-methylhex-5-enoic acid methyl ester **6**. Though psymberin belongs to the pederin family of natural products, psymberin **1** has distinct structural features from other members of the pederin family. For example, psymberin contains a six carbon amide side chain and a dihydroisocoumarin subunit and a structurally less-complex acyclic side chain. In this work, our synthetic strategy was to prepare anti configuration of methyl ester of psymberic acid and to compare methyl esters spectral data with the reported spectral data for the amide side chain of **1**. Notable features of this synthetic strategy include the implementing a modified protocol developed by Grieco¹⁷ to transform the primary alcohol to an olefin in presence of secondary alcohol as well as the application of Evans auxiliary-controlled addition reaction to obtain the anti diastereoselective fragment **8**.

Retrosynthetically, psymberic ester **4** can arise from diol **5** by selective elimination of the primary alcohol over the secondary alcohol developed by Grieco¹⁶ (Scheme 1). The diol can arise from **6** through three a three step reaction sequence which included: removal of the chiral auxiliary, esterification followed by hydrogenation. The anti diastereomer **6** is the predicted product of an asymmetric aldol addition reaction using Evans auxiliary-controlled addition reaction between aldehyde **7** and α -oxygenated amide derivative **8**.

The key bond forming reaction to obtain the anti-selectivity at the C4 and C5 positions on the amide side chain was achieved by an Evan's aldol reaction. The acylated oxazolidinone **8** was subjected to the Evans Sn(II) glycolate enolate protocol using aldehyde **7** and α -oxygenated amide derivative **8** to yield the *anti* aldol product **6** in 60% yield (Scheme 2). The stereochemical rational for the selectivity of the reaction remains to be unclear.¹⁷ However, Mukaiyama and coworkers postulate that in this reaction the product equilibration is slow. They assume the stereochemical outcome is determined by the possible binding of

TMEDA to the divalent tin enolate. This binding of TMEDA will change the coordination geometry of tin from tetragonal to octahedral and possibly favor a boat like transition state over the traditional chair transition state.^{17,18}

The aldehyde **7** was accessed from ozonolysis of alkene **11**, which was generated from ethyl-2-methyl 4-pentenoate **9** by a LAH reduction followed by PMB protection of the resulting alcohol **10** by 4-methoxybenzyl chloride. The amide **6** was obtained by a previously reported procedure by Evans and coworkers with benzyloxy acetyl chloride.¹⁹ Having the diastereomer **6** in hand, attention was turned to implicate several methods to protect the free hydroxy group in presence of the amide auxiliary. However, yields were insufficient and the starting material could not be recovered. Therefore, the chiral auxiliary was first removed with lithium hydroxide and hydrogen peroxide to obtain the free acid. The acid was immediately converted to methyl ester **12** by treating with diazomethane, which was subsequently *o*-methylated with methyl trifluoromethanesulfonate to provide methyl ether **13** (88% ee). Deprotection of the benzyl and PMB protecting groups under palladium-catalyzed hydrogenation provided compound **5**. The primary alcohol was selectively converted to the primary selenide using the protocol developed by Grieco¹⁶ in presence of secondary alcohol. Treatment of alcohol **5** with 2-nitrophenylselenocyanate and tributyl phosphine gave the intermediate selenide which was immediately oxidized with hydrogen peroxide to give the olefin **4** which was spectroscopically identical (¹H NMR, ¹³C NMR, IR, [α]_D) to the methyl ester reported by Floreancig *et al.*⁶

3. Conclusion

In conclusion, we have developed a viable strategy for the formation of chiral C1-C6 region of the psymberin side chain using Evan's chiral auxiliary. The synthesis was completed in 10 linear steps from the ethyl 4-methylpentenoate **9**. Significant transformations are Evans auxiliary-controlled addition reaction, formation of olefin from primary alcohol.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was carried out with the startup funds to William G. Bornmann from the University of Texas M D Anderson Cancer Center. We dearly thank Asha Nadipuram and David Maxwell for their assistance and encouragement.

References and notes

1. Pettit GR, Xu J, Chapuis J, Pettit RK, Tackett LP, Doubek DL, Hopper JNA, Schmidt JM. *J Med Chem.* 2004; 47:1149. [PubMed: 14971894]
2. Cichwicz RH, Valeriote FA, Crews P. *Org Lett.* 2004; 6:1951. [PubMed: 15176791]
3. Piel J, Butzke D, Fusetani N, Hui DQ, Platzer M, Wen GP, Matsuaga S. *J Nat Prod.* 2005; 68:472. [PubMed: 15787465]
4. Narquizian, R.; Kocienski, PJ. The Pederin Family of Antitumor Agents: Structures, Synthesis and Biological Activity. In: Mulzer, J.; Bohlmann, R., editors. *The Role of Natural products in Drug Discovery*. Springer; New York: 2000. p. 25Ernst Schering Research Foundation Workshop 32

5. Kiren S, Williams LJ. *Org Lett.* 2005; 7:2905. [PubMed: 15987166]
6. Green ME, Rech JC, Floreancig PE. *Org Lett.* 2005; 7:4117. [PubMed: 16146366]
7. Jiang X, Garcia-Fortanet J, De Brabander JK. *J Am Chem Soc.* 2005; 127:11254. [PubMed: 16089449]
8. Huang X, Shao N, Palani A, Aslanian R, Buevich A. *Org Lett.* 2007; 9:2597. [PubMed: 17523653]
9. Smith AB III, Jurica JA, Walsh SP. *Org Lett.* 2008; 10:5625. [PubMed: 19072197]
10. Crimmins MT, Stevens JM, Schaaf GM. *Org Lett.* 2009; 11:3990. [PubMed: 19670853]
11. Watanabe T, Imaizumi T, Chinen T, Nagumo Y, Shibuya M, Usui T, Kanoh N, Iwanbuchi. *Org Lett.* 2010; 12:1040. [PubMed: 20141170]
12. Chihui A, Hoyer AT, Smith AB III. *Org Lett.* 2012; 14:4350. [PubMed: 22892009]
13. Feng Y, Xin J, De Brabander JK. *J Am Chem Soc.* 2012; 134:17083. [PubMed: 23004238] For a review, see: Mosey MR, Floreancig PE. *Nat Prod Rep.* 2012; 29:980. [PubMed: 22772477]
14. Jiang X, Williams N, De Brabander JK. *Org Lett.* 2007; 9:227. [PubMed: 17217271]
15. Cheng-Yang W, Feng Y, Cardenas ER, Williams N, Floreancig PE, De Brabander JK, Roth MG. *J Am Chem Soc.* 2012; 134:18998. [PubMed: 23088155]
16. Grieco PA, Gilman S, Nishizawa M. *J Org Chem.* 1976; 41:1485.
17. Evans DA, Gage JR, Leighton JL, Kim AS. *J Org Chem.* 1992; 57:1961.
18. (a) Mukaiyama T, Iwasawa. *Chem Lett.* 1984; 13:753.(b) Zhang W, Carter RG, Yokochi AFT. *J Org Chem.* 2004; 69:2569. [PubMed: 15049660]
19. Evans DA, Glorius F, Burch JD. *Org Lett.* 2005; 7:3335. [PubMed: 16018654]

Figure 1.
Structure of psymberin and representative acylaminal-containing cytotoxic agents

Scheme 1.
Retrosynthetic Analysis.

Scheme 2.
Synthesis of C1-C6 portion of psymberin.